Citius Pharmaceuticals (CTXR) Minority Interest (2020 - 2026)

Citius Pharmaceuticals (CTXR) has reported Minority Interest for 7 consecutive years, with $9.3 million the latest figure, recorded in Q2 2026.

• For the quarter ending Q2 2026, Minority Interest rose 271.46% year-over-year to $9.3 million; the trailing twelve-month figure through Jun 2026 stood at $9.3 million (up 271.46% YoY), and the FY2025 full-year result was $10.0 million, up 147.92% from the prior year.
• Minority Interest advanced to $9.3 million in Q2 2026 per CTXR's latest filing, from $7.5 million in the prior quarter.
• Across five years, Minority Interest topped out at $13.5 million in Q4 2025 and bottomed at $600380.0 in Q1 2022.
• Historically, Minority Interest has averaged $3.3 million across 5 years, with a median of $600380.0 in 2022.
• The sharpest annual moves came in 2022 and 2024: Minority Interest changed 0.0% in 2022, then soared 570.31% in 2024.
• Over 5 years, Minority Interest stood at $600380.0 in 2022, then changed by 0.0% to $600380.0 in 2023, then soared by 484.86% to $3.5 million in 2024, then surged by 284.74% to $13.5 million in 2025, then plunged by 31.2% to $9.3 million in 2026.
• According to Business Quant data, Minority Interest over the past three periods registered $9.3 million, $7.5 million, and $13.5 million for Q2 2026, Q1 2026, and Q4 2025 respectively.